Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Gefitinib in EGFR-mutant NSCLC with BIM Polymorphism
NCT02151721Phase 1Unknown
- Sponsor
- Kanazawa University
- Start
- Jun 2014
- Primary completion
- Feb 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorinostat in non-small cell lung cancer (NSCLC), sponsored by Kanazawa University. Primary endpoint: Maximum Tolerated Dose at Day 28. Status: unknown.
02
Drugs
vorinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02151721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151721.